ArQule, Inc. (NASDAQ:ARQL)

Hoping the market notices ARQL is well positioned to possibly ride on the coat-tails of Exel's drug XL184...

currently 90 shares in my portfolio.

MB7

tenmiles

Mr. negative here, uncharacteristically giving a green thumb to a biotech stock. But if the phase III results are solid for the combination of ARQ 197 and Tarceva, and given Astellas' current pursuit of OSIP (markets Tarceva), the future looks bright for ARQL.

Bought based on feedback from a couple of friends in the oncology industry. Small position. yrs away from knowing the outcome. Some smart money likes what they see. Who knows. Pretty much dead money for the near term

I like the below $10 price and its potential for a good return.

This issue has too many LARGE investment banks/investors putting $$$ into it. Currently (late April 2008) it has been beaten to a point where an entry at this level will "probably" provide 100% ROI. Everyone is responsible for their own due diligence. This is one that has GREAT potential!!!

I think this an upcoming stock, although it fluctuates it is a strong stock.

best wall street player likes it, there probably smarter than me, so im going for it.

2 hottest new best in class cancer drug programs in phase 2: c-met and E2F1 checkpoint activators should lead to good deals, broad application, high efficiency, negligible side effects.

Safety profile of their C-Met inhibitor should win out over the Exelixis inhibitor in the clinic.

If the next phase of clinical trials goes well. This company will be set for the remainder of its life. Worth a look

The Cancer Survival Protein modulation program
is a home run for this small growing company.

takeover candidate

A biotech that is starting to hit its stride. The stock is starting to move regularly and in the right direction.

just gonna try getting in at this hoping for something good
at $7.30
might be a short or might go long.

ArQule is developing a portfolio of proprietary small molecule drugs to treat cancer. The company’s technology platform includes the Activated Checkpoint Therapy (ACT) program, which seeks to harness the cell's natural defense mechanism against genetic (DNA) damage. While ArQule was previously a leading chemistry services company, since mid-2006, it has repositioned itself as an oncology company focused on developing internally discovered drug candidates.

The company's cancer product, ARQ 501, currently in a Phase II trial, which is based on its ACT platform, plans to announce Phase II results from ARQ 501 around mid-2007. The company's second clinical-stage product, ARQ 197, completing Phase I clinical trial, is designed to trigger death in cancer cells. It expects to initiate Phase II trials in second quarter of 2007. ArQule also has a number of pre-clinical programs based on product candidates directed towards molecular targets.

The company’s revenue, which is currently derived from research and development funding from its alliance with Hoffmann-La Roche, Inc. (Roche), remained flat at $6.6 million, for the year ended December 2006. Revenue from its chemistry services business ceased in the second quarter of 2006 as a result of its strategic decision to exit this business and the subsequent decision by Pfizer to terminate its agreement with effect from May 2006.

ArQule looks like an attractive investment proposition on the premise that ARQ 501 is completing a broad Phase II development program, its partnership with Roche for ARQ 501 which is worth up to $276 million in research funding and clinical development milestones and a series of pre-clinical oncology programs utilizing the ACT platform. Compared to fiscal 2006, the company’s management expects to generate revenues in excess of 8% during fiscal 2007.

Carefully watching this stock, hoping for some positive news.